Clark Appointed as Interim CFO at Kiromic BioPharma
6 October 2021 - - US-based biotechnology company Kiromic BioPharma, Inc. (NASDAQ: KRBP) has appointed Daniel Clark as interim chief financial officer, the company said.

Kiromic's previous CFO, Tony Tontat, resigned on September 29, 2021, effective immediately.

Clark joined Kiromic in February 2020 and served as the company's Corporate Controller until September 2021, when he was promoted to vice president finance operations.

Before joining the company, Clark was a manager with The Siegfried Group, a national accounting services firm, from June 2018 to February 2020.

Prior to his employment with The Siegfried Group, Clark served as Senior Consultant - Office of the CFO Solutions for FTI Consulting, a global financial consulting firm, from January 2017 to May 2018. Prior to that, Clark was Senior Associate - Audit at KPMG US, a member of Big Four global accounting firm KPMG, from August 2011 to June 2015.

Kiromic BioPharma is an AI-driven, end-to-end CAR-T and gene therapy company, developing the first multi-indication allogeneic CAR-T cell therapy, that exploits the natural potency of Gamma Delta T-cells to target solid cancers.

Kiromic BioPharma is focused on discovering, developing, and commercializing novel immune-oncology applications through its product pipeline. The pipeline development is leveraged through the company's proprietary target discovery engine called "DIAMOND."